PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

por Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Publicado 2016

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Ph...

por Gelderblom, Hans, Jones, Robin L., George, Suzanne, Valverde Morales, Claudia, Benson, Charlotte, Jean-Yves Blay, Renouf, Daniel J., Doi, Toshihiko, Le Cesne, Axel, Leahy, Michael, Hertle, Sabine, Aimone, Paola, Brandt, Ulrike, Schӧffski, Patrick
Publicado 2020

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

por Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe
Publicado 2021

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

por Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, Hochhaus, Andreas
Publicado 2021